Blog Single

Halifax, Nova Scotia — (Newsfile Corp. – June 26, 2024) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the “Study”) indicates that, beyond shrinking tumors on its own, Sona’s Targeted Hyperthermia Therapy (“THT”) also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2.  (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.   

Sona’s Chief Medical Officer and the Study’s principal investigator, Dr. Carman Giacomantonio, commented, “With two separate murine cancer models completed, we now believe it is clear that Sona’s THT therapy causes cancer specific proteins (cancer antigens) to become visible to the immune system. This in turn causes novel, innate immune responses ultimately enabling development of cancer-specific immunity. This is essentially the goal of all current immunotherapy research and treatment strategies. When combined with a standard of care immunotherapeutic drug (IL-2), the resultant immunity in our models was strong enough to generate an immune response in remote (contralateral) tumors. Finally, we were excited to observe that the immunity generated by Sona’s gold nanorod-based THT therapy in our preclinical models is lasting.  In other words, we observed a “vaccine effect” whereby we were unable to immediately grow new tumors in mice whose primary tumors had responded to Sona’s gold nanorod THT therapy combined with standard immunotherapy.  This is the proof of concept we were looking for.”